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Expression of oncogenic K-RAS in primary cells elicits oncogene-induced cellular
senescence (OIS), a form of growth arrest that potently opposes tumourigenesis.
This effect has been largely attributed to transcriptional mechanisms that
depend on the p53 tumour suppressor protein. The PML tumour suppressor
was initially identiﬁed as a component of the PML-RARa oncoprotein of acute
promyelocytic leukaemia (APL). PML, a critical OIS mediator, is upregulated by
oncogenic K-RAS in vivo and in vitro. We demonstrate here that oncogenic K-RAS
induces PML protein upregulation by activating the RAS/MEK1/mTOR/eIF4E
pathway even in the absence of p53. Under these circumstances, PML mRNA
is selectively associated to polysomes. Importantly, we ﬁnd that the PML 50
untranslated mRNA region plays a key role in mediating PML protein upregula-
tion and that its presence is essential for an efﬁcient OIS response. These ﬁndings
demonstrate that upregulation of PML translation plays a central role in onco-
genic K-RAS-induced OIS. Thus, selective translation initiation plays a critical role
intumoursuppression with importanttherapeutic implications forthetreatment
of solid tumours and APL.
INTRODUCTION
When bound to GTP, the RAS family of small guanosine
triphosphatases activates several signalling pathways that
transduce critical cell proliferation and survival signals. Three
members of the family, H-RAS, K-RAS and N-RAS, acquire
transforming potential as a result of a single amino-acid
substitution most commonly at position 12 (oncogenic RAS;
Malumbres & Barbacid, 2003).
About 20% of all human tumours harbour oncogenic K-RAS
mutations. These mutants transform most immortalized cell
lines and initiate tumourigenesis in mouse cancer models
(Downward, 2003). However, it has become apparent that
oncogenic K-RAS signalling in primary cells also triggers
oncogene-induced cellular senescence (OIS), a potent growth-
suppressive response that opposes cancer progression (Campisi
& d’Adda di Fagagna, 2007). Oncogenic K-RAS controls the
RAF/MEK1/ERK1/2 and the PI3K/AKT signalling pathways.
Both of these have been implicated in OIS induction (Chen et al,
2005; Lin et al, 1998).
Oncogenic K-RAS may lead to increased translation efﬁciency
of existing mRNAs through several downstream effectors such
as ERK1/2 and AKT. These protein kinases regulate initiation of
translation by phosphorylating and inactivating TSC2, a tumour
suppressor that in a complex with TSC1 inhibits the mTOR
protein kinase (Ma et al, 2005; Manning et al, 2002). mTOR
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directly phosphorylating the 4E-BP family of translational
repressors and causing their dissociation from eIF4E, a
component of the eIF4F protein complex. This event leads to
the recognition of the 50-cap structure by eIF4E and mRNA
recruitment to ribosomes. Therefore, mTOR activation pro-
motes translation initiation. In addition, mTOR phosphorylates
and activates S6 ribosomal kinases (S6K1/2), which have been
implicated in the control of cell growth via increased mRNA
translation (Hay & Sonenberg, 2004).
The promyelocytic leukaemia tumour suppressor (PML),
initially identiﬁed as a component of the PML-RARa oncopro-
teinofacutepromyelocyticleukaemia(APL),playsacriticalrole
in oncogenic K-RAS-induced OIS. In this context, PML protein
levels are strikingly upregulated (Ferbeyre et al, 2000; Pearson
et al, 2000). The increase in PML protein levels leads to
recruitment of p53 to the PML-nuclear bodies (PML-NBs), an
event that facilitates p53 acetylation and transcriptional
activation (Bernardi & Pandolﬁ, 2007; Ferbeyre et al, 2000;
Pearson et al, 2000). Thus far, the increase in PML protein levels
in conditions of oncogenic stress has been attributed to
upregulation of PML gene transcription and it has been reported
that PML is a p53 transcriptional target gene (de Stanchina et al,
2004).
Here, we report that PML expression is also regulated at the
translational level during oncogenic K-RAS-induced OIS in a
p53-independent manner. We show that mTOR-dependent
translational control mechanisms are critically important in
modulating PML protein levels during oncogenic K-RAS-
induced OIS and that the PML 50UTR is necessary for efﬁcient
OIS induction. We propose that the mechanisms controlling
selective translation initiation of tumour suppressor proteins
play an important role in the cellular response to oncogenic
stress.
RESULTS
Oncogenic K-RAS upregulates PML protein in vivo in the
presence or absence of p53
To obtain insights into the networks controlling OIS induction,
we tested whether oncogenic K-RAS expression leads to PML
protein upregulation in vivo. We determined Pml protein levels
in the lungs of CCSP-rtTA/Tet-op-K-Ras mice. Exposure of these
mice to doxycycline (dox) leads to expression of oncogenic
K-Ras in the respiratory epithelium and development of
adenocarcinomas (NSCLC) within weeks of dox administration
(Fisher et al, 2001). Western blot (WB) analysis of lung lysates
revealed that Pml protein is upregulated in the lungs as early as
2 weeks after starting dox treatment. (Fig 1A). Immunohisto-
chemical (IHC) analysis revealed that Pml protein upregulation
occurs preferentially in neoplastic tissue (Fig 1B). It has been
suggested that PML is a p53 transcriptional target gene (de
Stanchina et al, 2004). Unexpectedly, however, we found that
Pml protein is upregulated in oncogenic K-Ras induced NSCLC
also in p53 null mice (Fig 1B). These results suggest that PML
protein is upregulated in vivo independently of p53 status.
Oncogenic K-RAS upregulates PML protein in MEFs
independently of p53
Primary mouse embryonic ﬁbroblasts (MEFs) and diploid
human ﬁbroblasts are well-established experimental model of
oncogenic K-RAS-induced OIS (Campisi & d’Adda di Fagagna,
2007;Ferbeyre etal,2000; Naritaetal, 2006;Pearson etal, 2000;
Serrano et al, 1997). Therefore, to understand the mechanism of
p53-independent PML upregulation, we tested whether Pml
protein upregulation would also occur in primary MEFs lacking
p53. Indeed, we found that oncogenic K-RAS induces upregula-
tion of Pml and ofthe number and size of PML-NBs both in wild-
type (WT) and in p53 null MEFs (Fig 1C and D).
We obtained equivalent results when we expressed onco-
genic H-RAS (Fig 1A of Supporting Information). We conﬁrmed
these results in p53 null MEFs harbouring a dox-regulated
oncogenic K-Ras transgene and a reverse tetracycline transacti-
vator (rtTA; p53 null rtTA/K-Ras MEFs; Pao et al, 2003).
Incubation of these cells with dox resulted in a time-dependent
upregulation of phospho-Erk (P-Erk) together with a concomi-
tant upregulation of Pml (Fig 1E). Conversely, withdrawal of
dox resulted in down-regulation of P-Erk and return of Pml
protein to basal levels (Fig 1F). Furthermore, oncogenic K-RAS
induces PML also in IMR90 and in BJ diploid human ﬁbroblasts
(Fig 1B–D of Supporting Information). Finally, oncogenic K-RAS
upregulates PML in human ﬁbroblasts also in conditions of OIS
bypass (Fig 1E of Supporting Information). These observations
indicate that the networks responsible for PML upregulation are
conserved between murine and human cells and that their
activation occurs also in conditions that evade OIS.
Taken together, these data corroborate our in vivo observa-
tions and conﬁrm that oncogenic K-RAS signalling induces PML
protein upregulation in a p53-independent manner.
PML upregulation by oncogenic K-RAS is independent of PML
transcription and dependent on mTOR and eIF4E
We next investigated whether PML protein upregulation upon
oncogenic K-RAS signalling is due to either transcriptional or
post-transcriptional mechanisms. We observed no signiﬁcant
differences in Pml mRNA levels by quantitative real-time PCR in
p53nullMEFsfollowingtransductionwithBabeK-RASorinp53
null rtTA/K-Ras MEFs exposed to dox for 24h (Fig 2A and B). In
WT MEFs (i.e. with a competent p53 response), Pml mRNA was
modestly upregulated by oncogenic K-RAS (Fig 2C). We
therefore hypothesized that post-transcriptional mechanism(s)
support the upregulation of Pml in bothp53 null and WT genetic
backgrounds.
To test whether PML upregulation involves regulation of
protein synthesis, we assessed whether PML upregulation is
affectedbyrapamycin,aspeciﬁcmTORinhibitor.Wefoundthat
this agent abrogated PML protein upregulation in p53 null rtTA/
K-Ras MEFs exposed to dox (Fig 3A and Fig 2A of Supporting
Information).
Induction of PML by oncogenic K-RAS requires MEK1/2
and TSC2
The RAF/MEK/ERK1/2 signalling cascade is both necessary and
sufﬁcient for the establishment of oncogenic K-RAS-induced OIS
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signalling cascade is also involved in mediating PML protein
upregulation. We found that treatment of p53 null MEFs
expressing oncogenic K-RAS with UO126, a speciﬁc MEK1/2
inhibitor, abrogates Pml protein upregulation (Fig 3B). Next, we
assessed the effect of MEK1/2 activation on Pml protein level by
expressing MEK
Q56P, an activated MEK1 mutant, in p53 null
MEFs and found that its expression is sufﬁcient to upregulate
Pml (Fig 3C).
We have previously demonstrated that ERK1/2 inactivates
TSC2 through a direct phosphorylation event, which leads to
TSC2dissociationfromTSC1andimpairmentofTSC2inhibition
of mTOR signalling (Ma et al, 2005). Thus, an ERK1/2 non-
phosphorylatable TSC2 mutant (TSC2A2) signiﬁcantly hinders
the ability of ERK1/2 to activate mTOR (Ma et al, 2005). We
tested whether PML upregulation by oncogenic RAS requires
TSC2 inactivation by ERK1/2. To this end, we transduced p53
null MEFs with recombinant retroviruses expressing oncogenic
K-RAS, TSC2A2 or a combination of the two. We found that
TCSC2A2 expression signiﬁcantly impairs the ability of
oncogenic K-RAS to upregulate Pml protein while it did not
affect Pml protein levels in the absence of oncogenic K-RAS
(Fig 3D). Moreover, we found that expression of RhebQ64L, a
constitutively active mutant that inactivates TSC2 and activates
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Figure 1. Oncogenic K-RAS upregulates Pml protein in vivo and in vitro independently of p53.
A. WB in protein extracts from the lungs of CC10/rtTA/K-Ras mice fed with dox as indicated. W and N indicate WT and null genotype, respectively.
B. Pml was detected by IHC in lung sections of CC10/rtTA/K-Ras and CC10/rtTA/K-Ras/p53
 /  mice (four mice/group) fed with dox for the indicated lengths of
time. Brown staining indicated Pml positive staining after dox treatment.
C. WB of MEFs transduced with the indicated retroviruses.
D. Immunofluorescence of MEFs transduced with recombinant retroviruses. Genotypes are indicated. Green, endogenous Pml staining; blue staining, nuclear
DNA. Size bar: 5mm.
E. WB of Tet-o-K-Ras/p53
 /  MEFs transduced with a retroviral vector expressing rtTA, treated with dox as indicated.
F. WB of Tet-o-K-Ras/p53
 /  MEFs transduced with a retroviral vector expressing rtTA. Dox was added to the cultures for 48h and then withdrawn for the
indicated lengths of time.
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null MEFs (Fig 3E). These results strongly suggest that mTOR
activation is not only necessary, but also sufﬁcient to mediate
PML protein upregulation.
Since mTOR controls protein synthesis through direct
regulation of eIF4E and the ribosomal S6 protein (S6K), we
tested whether these molecules mediate PML protein upregula-
tion. siRNA knockdown of eIF4E resulted in abrogation of PML
protein upregulation by oncogenic RAS (Fig 3F), while siRNA-
mediated knockdown of the ribosomal S6 protein had no effect
on PML protein upregulation (unpublished observation).
Taken together, these data indicate that PML protein
upregulation depends on the RAS/MEK/ERK/mTOR signalling
cascade and that eIF4E is the ﬁnal effector of this signalling
cascade when pertaining to PML protein upregulation.
The PML 5(UTR mediates oncogenic K-RAS induced PML
protein upregulation
It is well known that eIF4E regulates selective translation of
mRNAs though recognition of their 50-cap structure, therefore,
we tested whether the Pml 50UTR is sufﬁcient to direct PML
protein upregulation in the presence of oncogenic RAS. The
National Center for Biotechnology Information (NCBI) database
lists two Pml mRNAs: NM_178087.2 and NM_008884.2. We
used RNA ligase-mediated rapid ampliﬁcation of 50 cDNA ends
(RLM-50RACE) to identify the predominant Pml mRNA species
in WT and p53 null MEFs. We found that the majority of the
transcripts contained a 96 nucleotide (nt.) long 50UTR
identical to NM_178087.2 (Fig 4A). A minor population of
transcripts contained heterogeneous 50 ends that were 62–91 nt.
long.
Notably, the mFOLD program (Zuker, 2003) predicted that
the major Pml 50UTR would contain an ordered stem and loop
structure (free energy of folding DG¼ 28kcal/mol; Fig 4A).
Todirectly evaluatetheimpactofthe50UTRintheregulation
of mouse Pml protein level we generated a plasmid vector in
which the CMV immediate-early promoter drives the expres-
sion of the 50UTR of mouse Pml fused to EGFP (p50UTR EGFP).
Transfectionofp50UTREGFPinp53nullMEFstransducedwith
the Babe K-RAS retrovirus led to signiﬁcantly increased levels
of EGFP when compared to cells transfected with the pEGFP
parental control vector. In contrast, we noted no signiﬁcant
differences in EGFP protein levels following transfection of p53
null MEFs with either p50UTR EGFP or pEGFP (Fig 4B).
Transfection efﬁciency for the experiments was monitored by
adding a Renilla expression vector to the transfection mix (Fig
2B of Supporting Information). We assessed the effects of
rapamycin, UO126 and of the PI3K inhibitor LY294002 on the
levels of EGFP produced by p50UTR EGFP following transfec-
tion in p53 null MEFs transduced with babe K-RAS or Babe
puro. We found that rapamycin or UO126 signiﬁcantly reduced
t h el e v e l so fE G F Pp r o d u c e da f t e rt r a n s f e c t i o ni nB a b eK - R A S -
transduced cells, while the PI3K inhibitor LY294002 had only a
minor effect. In contrast, rapamycin or UO129 did not cause
any signiﬁcant effects in Babe puro-transduced cells (Fig 4C).
These data indicate that the Pml 50UTR is sufﬁcient to mediate
the effects of oncogenic K-RAS on Pml protein upregulation
and that this effect is dependent on the MEK/ERK/mTOR
signalling axis speciﬁcally in oncogenic K-RAS-expressing
cells.
Oncogenic K-RAS expression leads to recruitment
of Pml mRNA to polysomes
Next, we directly tested whether oncogenic K-Ras expression
leads to recruitment of Pml mRNA to polysomes in p53 null
rtTA/K-Ras MEFs exposed to dox, rapamycin, a combination of
the two or DMSO. We used a Polymerase Chain Reaction (after
reverse transcription) (RT-PCR) assay that tracks the polysomal
distribution of mRNAs in cellular extracts along a sucrose
gradient (Arava, 2003). We found that Pml mRNA signiﬁcantly
associates with polysomes when oncogenic K-Ras is expressed,
but not in control cells or in cells treated with the mTOR
inhibitorrapamycin.Importantly,wefoundthatPmlmRNAwas
distributed mainly to heavy polysomes, as expected for an
mRNA that is translated efﬁciently (Fig 4D). We determined that
PML mRNA is recruited to polysomes also in human
immortalized ﬁbroblasts with competent p53. As a positive
control, we used the mRNA of p27 Kip1, which is recruited to
polysomes during oncogenic stress (Fig 2C of Supporting
Information; Rajasekhar et al, 2003). These results provide
evidence that oncogenic K-RAS-induced PML upregulation is
due also to enhanced PML mRNA translation.
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Figure 2. Pml upregulation upon oncogenic K-Ras does not depend on Pml
transcription and is sensitive to rapamycin.
A. Histogram showing Pml/Actin mRNA ratio in p53 null MEFs following
transduction with Babe Puro (black bar) or Babe Puro RAS (white bar).
B. Histogram shows Pml mRNA/HPRT mRNA ratio in Tet-o-K-Ras/p53
 / 
MEFs expressing rtTA. Black bar, untreated MEFs; white bar, MEFS treated
with dox for 24h.
C. Histogram shows Pml mRNA/Actin mRNA ratio in primary MEFs with WT
p53 transduced with the indicated retroviruses. Data were obtained from
three-independent experiments performed in triplicate. Error bars: stan-
dard deviations.
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cellular senescence
Finally, we tested the role of the PML 50UTR in directing OIS
induction in immortalized human ﬁbroblasts. To this end, we
generated retroviruses expressing either the PML open reading
frame (LNC PML) or the PML cDNA fused to the 50UTR (LNC
50UTRPML).LNCPML,LNC50UTRPML,andtheparentalLCNX
viruses were used to transduce IMR90 human ﬁbroblasts. After
drug selection with neomycin, cultures were further transduced
either with Babe puro or Babe K-RAS retroviruses. PML protein
levels were evaluated 6 days after completion of selection with
puromycin. This analysis revealed that the PML protein was
signiﬁcantly upregulated by oncogenic K-RAS in IMR90
ﬁbroblasts transduced with LNC 50UTR PML, when compared
to cells transduced with LNC PML (Fig 4E). Moreover, we found
that in IMR90 ﬁbroblasts expressing oncogenic K-RAS, trans-
duction with LNC 50UTR PML further suppresses cellular
proliferation as compared to transduction with LNC PML
(Fig 4F), which correlated with an increase in the percentage of
cells expressing the OIS marker senescence associated b-
galactosidase (SA-b-Gal; Fig 2D of Supporting Information).
Next, we determined the effect of a PML cDNA including its
50UTR on cellular proliferation of p53 null MEFs. The p53
tumour suppressor is essential for OIS (Campisi & d’Adda di
Fagagna, 2007). As expected, we did not detect any effects on
OIS. However, we noticed that the PML cDNA comprising its
50UTR was capable of modestly decreasing cell proliferation in
p53 null MEFs expressing oncogenic K-RAS (Fig 2E of
Supporting Information). We also found that expression of
PML cDNA, irrespectively of the presence of its 50UTR, did not
affect oncogenic K-RAS-induced OIS in Pml null MEFs
(unpublished observation). This observation is in agreement
withthereportthatectopicexpressionofasinglePMLisoformis
not sufﬁcient to induce OIS in Pml null MEFs (Bischof et al,
2002).
Takentogether,these dataindicate thatthePMLupregulation
mediated by its 50UTR is of biological signiﬁcance. These
observations are also consistent with the notion that PML has
p53-independent antiproliferative effects (Bernardi & Pandolﬁ,
2007; Wang et al, 1998).
DISCUSSION
Thusfarit has been thought thatPMLupregulation in conditions
of cellular stress is due to transcriptional mechanisms (Bernardi
& Pandolﬁ, 2007; Chelbi-Alix et al, 1995; de Stanchina et al,
2004). Our ﬁnding that translation initiation mechanisms
contribute to PML protein upregulation upon oncogenic stress
challenges this view and provides novel insights into the
molecular mechanisms regulating oncogenic K-RAS-induced
OIS. We also ﬁnd that PML protein upregulation can also occur
independently of transcriptional mechanisms that require p53.
Thus, since PML has p53-independent tumour suppressor
properties, this mechanism may also provide a back-up tumour
suppressor mechanism in cancer cells that are p53-deﬁcient.
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Figure 3. Oncogenic K-RAS induced PML protein
upregulation depends on MEK1 and TSC2.
A. WB of Tet-o-K-Ras/p53
 / /rtTA MEFs treated
with dox and rapamycin as indicated.
B. WBofp53nullMEFstransducedandtreatedwith
U0126 as indicated.
C. WB of p53 null MEFs transduced with the indi-
cated retroviruses.
D. WB analysis of p53 null MEFs transduced as
indicated.
E. WB of p53 null MEFs following retroviral trans-
duction.
F. WB analysis of tet-o-K-Ras/p53
 / /rtTA following
siRNA transfection and dox treatment. The
intensity of the bands is expressed with the
indicated ratios.
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with a rapid response to external and internal stressors, as
opposed to a slower response mediated by nuclear pathways of
mRNA synthesis and subsequent nuclear export. For these
reasons,wedesignedourexperimentstospeciﬁcallyaddressthe
mechanisms regulating PML protein abundance in conditions of
acute exposure to oncogenic stress.
Control of translational regulation occurs mostly at the rate-
limiting initiation step, which is controlled by the cap-binding
protein eIF4E. Our discovery that the 50UTR sequence of the Pml
gene is essential for oncogenic K-Ras-induced upregulation of
Pml is consistent with the notion that changes in the 4E-BPs/
eIF4E ratio do not alter general translation, but rather affect the
translation of a subset of mRNAs that harbour a structured
50UTR (Hay & Sonenberg, 2004). Signiﬁcantly, analysis of the
human PML 50UTR sequence listed in the NCBI database
revealed a sequence of 87 nt. that folds into a stem and loop
structure that closely resembles its murine counterpart
(unpublished observation), suggesting that the mechanism of
PML upregulation that we have uncovered is not restricted to
mouse cells. Accordingly, we have found that PML is
upregulated by oncogenic K-RAS both in murine and in human
ﬁbroblasts. These observations suggest that the mechanisms
leading to PML upregulation in the presence of oncogenic RAS
are conserved between murine and human cells.
We propose that 50UTR-dependent PML upregulation is a
mechanism that allows the cell to acutely counteract inappropri-
ate growth stimuli by directly activating protein translation
through a MEK/mTOR/eIF4E signalling axis, while slower
transcription-dependent mechanisms are activated (Fig 4G). In
this regards, our data complement and extend a previous report
indicatingthatPMLisap53targetgene(deStanchinaetal,2004).
Our report lends support to the emerging notion that
translation-dependent mechanisms play a critical role in the
OIS response (Petroulakis et al, 2009). We suggest that these
mechanisms are not limited to OIS or to PML regulation but may
rather be of general signiﬁcance in cellular responses to stress.
Indeed, it has been shown that p53 protein levels are controlled
at the translational level upon DNA damage induced by ionizing
radiation (Mazan-Mamczarz et al, 2003; Takagi et al, 2005).
Since the initial descriptionthatoncogenic K-RAS inducesOIS,
it has been discovered that the activation of several oncogenic
networks can cause OIS. For instance, PTEN inactivation may
lead to PTEN-loss-induced cellular senescence (PICS), a type of
cellular senescence distinct from OIS, through a mechanism that
requires translational upregulation of the p53 (Alimonti et al,
2010). Therefore, it is tempting to speculate that PML, which is a
p53 co-factor, may also be upregulated in PICS positively
regulating p53, which can be addressed in further studies taking
advantage of knockout models. Furthermore, the regulation of
Research Article
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Figure 4. The Pml 5(UTR mediates oncogenic
K-RAS-induced PML protein upregulation.
A. Primary sequence of the Pml 50UTR folded by the
mFOLD algorithm. Underlined letters indicate
Pml ATG. Energy of folding is indicated.
B. WB analysis of p53 null MEFs stably transduced
with Babe K-RAS or Babe puro. After selection,
cells were transfected as indicated. The intensity
of the bands is indicated as a ratio between EGFP
and tubulin.
C. WB analysis of p53 null MEFs transduced and
treated as indicated. The ratio between the
intensity of EGFP and Hsp90 is indicated.
D. Graph shows Pml RNA levels detected by RT-PCR
in cytoplasmic cell extracts of p53 null rtTA/K-Ras
MEFs fractionated through a sucrose gradient
and to obtain polyribosome fractions. Cells were
treated with dox for 24h with or without rapa-
mycin.
E. WB analysis of IMR90 cells transduced with
LNCX, LNC 50UTR PML or LNC PML, after selection
cells were either transduced with babe puro or
babe K-RAS retroviruses.
F. The graph shows cell proliferation assays of
IMR90 cells transduced as indicated. Asterisk
indicates statistical significance between cells
transduced with LNC PML and LNC-50UTR PML.
The curve represents the result of three-inde-
pendent experiments performed in triplicate.
Standard deviations were not drawn when too
small to appear on graph.
G. Molecular mechanisms controlling PML-
mediated OIS induction. RE¼p53 responsive
element.
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signalling pathways and feedback mechanisms. For instance, it
has been reported that the activation of the PI3K signalling
pathway overcomes oncogenic K-RAS-induced OIS, while others
have reported that OIS is due to negative feedback response that
potently suppresses oncogenic K-RAS signalling (Courtois-Cox
etal,2006;Kennedy etal,2011).The formerscenario shouldlead
totheupregulationofPMLthroughactivationofmTOR,whilethe
second is expected to downregulate it.
Of note, PML can act as a negative regulator of mTOR
(Bernardi et al, 2006). Therefore the mTOR-dependent upregu-
lation of PML in response to stress could not only lead to cellular
senescence when cells are unable to cope with aberrant
oncogenic signalling, but also represent a way to tune the
mTOR-dependent translational output. The role of these
possible feedback mechanisms should be ultimately assessed
in vivo in mouse cancer models.
Several mTOR inhibitors are used in the treatment of cancer
patients. Our work has therefore potential clinical implications
since the ability of rapamycin to block PML upregulation in OIS
could limit the efﬁcacy of this drug when cellular senescence is a
desirable therapeutic outcome. Future studies are therefore
warranted to evaluate whether therapies that target the transla-
tional apparatus may lead to unintended and counterproductive
effects during the treatment of cancers where tumour suppressor
proteins are upregulated due to translational mechanisms.
On the other hand, our data suggest that in APL where the
PML 50UTR is fused to the RARa moiety of the PML-RARa
oncoprotein, mTOR inhibitors may be extremely beneﬁcial
because they would block the translation of the oncogene while
globally opposing cell growth and proliferation.
MATERIALS AND METHODS
Mouse strains
P53
 / , CCSP-rtTA/Tet-op-K-Ras, and b-actin TVA transgenic mice
were bred to generate compound mutant mice (Fisher et al, 2001;
Jacks et al, 1994; Orsulic et al, 2002). Starting at 8 weeks of age, CCSP-
rtTA/Tet-op-K-Ras and CCSP-rtTA/Tet-op-K-Ras/p53
 /  mice were
maintained either on standard or dox containing diet (625ppm;
Harlan-Teklad). Animal studies were performed in accordance to
institutional policies.
Cell culture, plasmids, retroviruses and cellular senescence
assays
IMR90 and BJ human diploid fibroblasts were obtained from the ATCC
and used between passage 10 and 20. These cell lines have the
capacity to undergo more than 50 population doublings in culture
before undergoing senescence (Nichols et al, 1977; Yi et al, 1999). Day
12–14 mouse embryonic fibroblasts were derived as described
previously (Scaglioni et al, 2006). The PML isoform IV expression
vector was cloned in the TAG2B expression vector (Agilent Technol-
ogies) described previously. pBabe puro, pWzl Hygro, pBabe K-RAS and
pBabe H-RAS were obtained from Addgene. LNCX was obtained from
Dr. Dusty Miller (Fred Hutchinson Cancer Research Center). The RCAS-
rtTA virus was obtained from Dr. Harold E. Varmus. pBabe puro
RhebQ64L and pbabe puro MEK1 Q56P were generated by site
directed mutagenesis. Recombinant retroviruses were generated as
described (Pao et al, 2003; Pear et al, 1993). The p50UTR EGFP
construct was generated by cloning the Pml 50UTR sequence into
pEGFP-N (Clontech). LNC 50UTR PML was obtained by cloning the
murine Pml 50UTR sequence directly in front of human PML IV in the
polylinker of LNCX. Dox was added to cell cultures at a concentration
of 1mg/ml. SA-b-Gal assays were performed as described (Scaglioni
et al, 2006). Every experiment was repeated at least three times with
equivalent results. Transfections were performed with the effectene
reagent (Qiagen). Transfection efficiency for the experiments shown in
Fig 4B was monitored by adding the pRL Renilla expression vector
(Promega) to the transfection mix.
Immunoblotting, chemicals and antibodies
Immunoblotting was performed with the following antibodies: anti-
Flag (Sigma), anti-GFP (Cell Signaling), anti-PML 36.1-104 (Millipore),
anti p-ERK1/2, ERK1/2 and anti-eIF4E (Cell Signaling Laboratories),
anti-pan RAS (Abcam), anti-actin and anti HSP90 (Sigma). Specific
bands were quantified by densitometry. Chemicals were from
Calbiochem, Sigma or Invitrogen.
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The paper explained
PROBLEM:
Oncogene-induced premature cellular senescence (OIS) is a critical
tumour suppressor mechanisms that induces a permanent
proliferative arrest. Drug therapies that either promote or suppress
OIS may significantly impact tumourigenesis in cancer patients.
RESULTS:
Inthiswork,wereportthatthepromyelocytictumoursuppressor
(PML), a critical inducer of cellular senescence, is upregulated by
oncogenic K-RAS through translation-dependent mechanisms
that require mTOR, eIF4E and the PML 50untranslated region.
IMPACT:
Thus far, induction of oncogene-induced cellular senescence has
been largely attributed to transcriptional mechanisms. Thus,
these findings unveil a novel mechanism regulating OIS.
Moreover, this data raise the concern that inhibitors of the PI3K/
mTOR pathway, which are developed as targeted cancer drugs,
maybluntOIScausingunexpectedandcounterproductiveeffects
in cancer patients.
600  2012 EMBO Molecular Medicine EMBO Mol Med 4, 594–602 www.embomolmed.orgRNA Interference, quantitative RT-real time PCR
and RLM-RACE
MEFs were transfected with eIF4E or S6 ribosomal protein siRNA
duplexes (eIF4E siRNA/siAb
TM Assay Kit-Upstate Cell Signaling Solu-
tions) or nonspecific control SMARTpool siRNA using siRNA Dharma-
FECT Transfection Reagent. Cells were analysed 48h after transfection.
Quantitative RT real time PCR was performed using Pml, actin and
hypoxantine phosphoribosyl transferase specific primers (TaqMan,
Gene Expression Assays). RLM-RACE was performed according to the
manufacturer instructions (Invitrogen). Every experiment was re-
peated at least three times with equivalent results.
Immunofluorescence and immunohistochemistry microscopy
Cell cultures were fixed and stained as described (Scaglioni et al,
2006).
Statistical analysis
Prism software was used for the statistical analysis. p-Values were
calculated using the unpaired Student’s t-test.
Isolation of polyribosomes and RNA
Polyribosome fractionation was performed following standard proce-
dures (Arava, 2003). Every experiment was repeated at least three
times with equivalent results.
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